March 21, 2025

Navigating the Storm in Pharma Wholesale

The pharmaceutical wholesale industry is facing unprecedented challenges. Tariffs, IRA pricing reforms, and new drug legislation are disrupting supply chains, squeezing margins, and forcing wholesalers to rethink their strategies.

What’s at Risk?

Tariffs may drive up costs on APIs, packaging, and medical devices.
IRA-driven pricing shifts could reduce reimbursement rates and impact profitability.
Supply chain vulnerabilities require new sourcing strategies to ensure product availability.

The pharmaceutical landscape is evolving, and those who act now will define the future. Get in-depth insights into how wholesalers can thrive amid market disruptions.

Download the Report

Press Releases

ALVAREZ & MARSAL BOLSTERS ITS HEALTHCARE PRACTICE IN SOUTHEAST ASIA (ASEAN) REGION WITH THE APPOINTMENT OF SANATH KUMAR AS MANAGING DIRECTOR

September 1, 2025

Leading global professional services firm Alvarez & Marsal (A&M) has announced the appointment of Sanath Kumar as Managing Director within its Southeast Asia and Australia (SEAA) business unit. Based in Singapore, Mr. Sanath will play a strategic role in building out A&M’s Healthcare and Life Sciences practice across ASEAN markets.

Thought Leadership

Next-Generation Antibodies: A New Era in Immuno-Oncology

August 25, 2025

As the immune checkpoint inhibitor (ICI) market nears a patent cliff, the $50B immuno-oncology (IO) field is now seeking to surpass the limitations of earlier ICIs by enhancing survival outcomes, broadening coverage, and overcoming resistance mechanisms.

Thought Leadership

Strategic Patience in GenAI - A smarter path to AI leadership

August 11, 2025

As Generative AI accelerates across industries, life sciences firms must seek to adopt strategic patience, prioritizing long-term enterprise value over generating short-term media headlines.

Thought Leadership

The U.S. Pharma Premium: Who’s Really Paying the Price?

June 30, 2025

For decades, the United States has shouldered a disproportionate share of global pharmaceutical costs, accounting for 70% of global biopharma profits and over 80% of new drug launches. While this has helped drive significant medical innovation and supported the majority of global drug launches, it has also resulted in higher out-of-pocket costs for American patients.

Authors